The purpose of this study is to evaluate safety and efficacy of Allogenic Umbilical Cord-derived Mesenchymal Stem Cell in Patients with Rotator Cuff Disease
Male or female 19 years of age and older.
Patients with unilateral shoulder pain lasting for at least 3months
Patients who do not respond to conservative treatment.
Patients who have not responded to sufficient non-surgical treatments, including medication, injection therapy, physical therapy, or exercise therapy, for more than 3 months
Patients who have received subacromial injection therapy on the affected shoulder within the past 3 months.
Patients who have undergone rotator cuff surgery on the affected shoulder within the past 6 months
Patients with a history of receiving stem cell therapy for the shoulder.
Patients with the following shoulder conditions: complete rotator cuff tear, adhesive capsulitis, or isolated acromioclavicular joint arthropathy.